Thursday, June 11, 2026
🇺🇸 FDA

pharma · Atherosclerosis · Non-small Cell Lung Cancer (NSCLC)

MSD Merck Sharp

Merck Sharp and Dohme

MSD Merck Sharp clinical programs — 82 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
WERFTESTRASSE 4, Lucerne, 6005, ch HQ
61 Employees
EMA registrant Type
Company details
Status
Public
HQ
WERFTESTRASSE 4, Lucerne, 6005, ch
Employees
61
Programs
217
Drugs
180
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

MSD Merck Sharp projects

82 ClinicalTrials.gov programs sponsored by MSD Merck Sharp.

MSD Merck Sharp has 82 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

82 programs

Clinical programs

Page 1 of 2

  1. A Clinical study of MK-4716 in people with certain solid tumors (MK-4716-001)

    Merck Sharp and Dohme

    Cancer – Solid Tumors : 1L NSCLC and all other advanced or metastatic solid tumors with KRAS alterations (KRAS mutation or KRAS amplification)

    phase 2 other active

    1 trial

  2. Belzutifan, PALBOCICLIB

    Merck Sharp and Dohme

    Advanced ccRCC

    phase 2 small molecule active

    1 trial

  3. Enpatoran Placebo, Enpatoran

    Merck Sharp and Dohme

    Systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)

    phase 2 small molecule active

    1 trial

  4. Ifinatamab Deruxtecan

    Merck Sharp and Dohme

    Esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  5. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Hematologic Malignancies or Solid Tumors in Pediatric and Young Adults

    phase 2 small molecule active

    1 trial

  6. KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Relapsed or refractory Classical Hodgkins Lymphoma and relapsed or refractory Primary Mediastinal Large B-cell Lymphoma

    phase 2 small molecule active

    1 trial

  7. M9140

    Merck Sharp and Dohme

    Gastric Cancer

    phase 2 small molecule active

    1 trial

  8. M9140

    Merck Sharp and Dohme

    Pancreatic Ductal Adenocarcinoma

    phase 2 small molecule active

    1 trial

  9. M9140

    Merck Sharp and Dohme

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. MK-1022-010

    Merck Sharp and Dohme

    High Risk Early-Stage Triple Negative Breast Cancer (TNBC) or Hormone Receptor Low Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR-low+/HER2-) Breast Cancer

    phase 2 small molecule active

    1 trial

  11. MK-1022-011

    Merck Sharp and Dohme

    Colorectal Carcinoma, Biliary Tract Carcinoma, Hepatocellular Carcinoma​

    phase 2 small molecule active

    1 trial

  12. MK-1026-003

    Merck Sharp and Dohme

    Chronic lymphocytic leukemia/Small lymphocytic lymphoma; Richters transformation; Mantle cell lymphoma, Marginal zone lymphoma; Follicular lymphoma; Waldenström’s macroglobulinemia

    phase 2 small molecule active

    1 trial

  13. MK-1084-014

    Merck Sharp and Dohme

    Neoplasm malignant with KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  14. MK-1167-008

    Merck Sharp and Dohme

    Alzheimer’s disease dementia

    phase 2 small molecule active

    1 trial

  15. MK-1200-002

    Merck Sharp and Dohme

    Advanced solid tumor

    phase 2 small molecule active

    1 trial

  16. MK-2060, Placebo to MK-2060

    Merck Sharp and Dohme

    Prevention of arteriovenous graft thrombosis

    phase 2 small molecule active

    1 trial

  17. MK-2140-006

    Merck Sharp and Dohme

    Aggressive and Indolent B-cell Malignancies (mantle cell lymphoma; chronic lymphocytic leukemia; follicular lymphoma; Richter’s syndrome)

    phase 2 small molecule active

    1 trial

  18. MK-2140-011

    Merck Sharp and Dohme

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  19. MK-2214-004

    Merck Sharp and Dohme

    Alzheimer’s Disease

    phase 2 small molecule active

    1 trial

  20. MK-2400-01A

    Merck Sharp and Dohme

    Metastatic castrate resistant prostate cancer - mCRPC

    phase 2 small molecule active

    1 trial

  21. MK-2870-027

    Merck Sharp and Dohme

    Intermediate-risk Non-muscle Invasive Bladder Cancer

    phase 2 other active

    1 trial

  22. MK-3120

    Merck Sharp and Dohme

    High-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors

    phase 2 small molecule active

    1 trial

  23. MK-3120

    Merck Sharp and Dohme

    Advanced/metastatic solid tumor disease

    phase 2 small molecule active

    1 trial

  24. MK-3475-01A

    Merck Sharp and Dohme

    non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  25. MK-3475-01B

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  26. MK-3475-01C

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  27. MK-3475-01E

    Merck Sharp and Dohme

    Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  28. MK-3475-01F

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  29. MK-3475-01H

    Merck Sharp and Dohme

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  30. MK-3475-01I

    Merck Sharp and Dohme

    Stage IV Squamous Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  31. MK-3475-01J

    Merck Sharp and Dohme

    Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous NSCLC

    phase 2 small molecule active

    1 trial

  32. MK-3475-02A

    Merck Sharp and Dohme

    PD-1 refractory melanoma

    phase 2 small molecule active

    1 trial

  33. MK-3475-02B

    Merck Sharp and Dohme

    PD-1 refractory melanoma

    phase 2 small molecule active

    1 trial

  34. MK-3475-02C

    Merck Sharp and Dohme

    Stage IIIB or IIIC or IIID melanoma

    phase 2 small molecule active

    1 trial

  35. MK-3475-02D

    Merck Sharp and Dohme

    Advanced melanoma with brain metastases, PD-1 refractory or PD-1 naive

    phase 2 small molecule active

    1 trial

  36. MK-3475-03A

    Merck Sharp and Dohme

    Renal cell carcinoma

    phase 2 small molecule active

    1 trial

  37. MK-3475-03B

    Merck Sharp and Dohme

    Renal cell carcinoma

    phase 2 small molecule active

    1 trial

  38. MK-3475-03C

    Merck Sharp and Dohme

    Clear cell renal cell carcinoma

    phase 2 small molecule active

    1 trial

  39. MK-3475-04B

    Merck Sharp and Dohme

    Advanced Urothelial Carcinoma

    phase 2 other active

    1 trial

  40. MK-3475-04C

    Merck Sharp and Dohme

    Advanced Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  41. MK-3475-04D

    Merck Sharp and Dohme

    Urothelial carcinoma

    phase 2 small molecule active

    1 trial

  42. MK-3475-06B

    Merck Sharp and Dohme

    Advanced esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  43. MK-3475-06C

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 small molecule active

    1 trial

  44. MK-3475-06D

    Merck Sharp and Dohme

    Gastroesophageal cancer

    phase 2 small molecule active

    1 trial

  45. MK-3475-06E

    Merck Sharp and Dohme

    Esophageal squamous cell carcinoma

    phase 2 small molecule active

    1 trial

  46. MK-3475-365

    Merck Sharp and Dohme

    Metastatic Castration-Resistant Prostate Cancer

    phase 2 small molecule active

    1 trial

  47. MK-3475-495

    Merck Sharp and Dohme

    Stage IV non-small cell lung cancer

    phase 2 small molecule active

    1 trial

  48. MK-3475-667

    Merck Sharp and Dohme

    Classical Hodgkin lymphoma in children and young adults

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does MSD Merck Sharp have?

82 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.